NHL Treatment Market Boom Will Be Hindered in EU

The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.

The company says that high unmet clinical needs and the launch of promising drugs will be key global drivers, although the patent expiry of blockbuster Rituxan in the EU will hinder market growth in this region.

GBI Research analyst Sravanthi Addapally says that while Rituxan has dramatically improved NHL patient prognosis and been the standard of care in front-line treatment regimens, there is increasing evidence of resistance to the drug. Overcoming this has been a major focus of recent therapeutic development. This treatment challenge will create space for the entry of three promising new therapies, which will ultimately drive NHL market growth.

“The second generation anti-CD20 monoclonal Antibody, ofatumumab, and the third generation anti-CD20 mAb, obinutuzumab, may be able to induce stronger complement-dependent cytotoxicity in rituximab-resistant cell lines. Additionally, the immunotherapeutic vaccine dasiprotimut-T has the potential to eliminate the risk of rituximab resistance,” says Addapally.

While Rituxan, or Mabthera “is expected to retain its superior share of the NHL treatment space, the cost decrease following the drug’s patent expiry will be the prime reason for the flat market in the EU.”

Further information can be found on the GBI Research website.